PEGBIO CO-B's stock surged 10.69% during intraday trading on Wednesday, marking a significant upward movement for the innovative drug company.

The sharp rise appears driven by two key positive developments. First, the company announced that cornerstone investors have voluntarily agreed to extend their lock-up period, demonstrating strong confidence in PEGBIO CO-B's future prospects based on its technological R&D capabilities and progress in key clinical milestones. Second, market focus has been redirected to the company's circRNA-LNP technology platform after its core pipeline candidate, CR059, was selected as a Late Breaking Abstract at the American Diabetes Association's Scientific Sessions, highlighting the new possibilities of its ultra-long-acting GLP-1 technology pathway for metabolic diseases.